Last reviewed · How we verify

NCT07380815: APART-LUNG

Physical Activity During Radiation Therapy for Lung Cancer

Not yet recruiting Last updated 2 February 2026
What this trial tests

trial in Prospective Study in 20 participants. Not yet recruiting.

Timeline
1 February 2026
Primary endpoint
30 April 2026
30 April 2026

Quick facts

Lead sponsorUniversity Hospital Schleswig-Holstein
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment20
Start date1 February 2026
Primary completion30 April 2026
Estimated completion30 April 2026

Conditions studied

Sponsor

University Hospital Schleswig-Holstein

Who can join

18 and older, any sex, with Prospective Study. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this trial is to evaluate patterns of physical activity during radiation therapy for lung cancer and to estimate the within-patient change in physical activity between Week 1 and Week 5 of radiation therapy, measured by smart phone-recorded step counts normalized for device carrying time. The trial is exploratory in nature with the aim to generate scientific hypotheses to be investigated in future clinical trials.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Assessment of Physical Activity During Radiation Therapy for Lung Cancer: Study Protocol of the APART-LUNG Study.
    Rades D, Streubel MK, Doehring L, Janssen S, et al · · 2026 · PMID 42041957 · DOI 10.3390/clinpract16040080

Verify or expand the search:

Other recruiting trials for Prospective Study

Currently open trials in the same condition.

Other University Hospital Schleswig-Holstein trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07380815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing